Navigation Links
Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
Date:3/6/2008

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2007, after the close of market on March 13, 2008. The company's earnings conference call will take place March 13, 2008, at 2 p.m. PDT (5 p.m. EDT).

Third-Quarter Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, March 13, 2008

Participants are invited to call 877-545-1491 or 719-325-4931. The live event will be available on Trubion's Web site at http://investors.trubion.com/events.cfm.

A replay of the discussion can be obtained beginning at 8 p.m. EDT March 13 by visiting Trubion's Web site or calling 888-203-1112 or 719-457-0820 and entering the code 7634379. The telephone replay will be available until midnight on Monday, March 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.

Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

TRBN-G

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals, Inc.

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Jenny Moede

Senior Vice President

503-443-7000

jmoede@wagged.com


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Trubion Announces Presentations at Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to help ... Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. Bernie ... pass through tough times, Dr. Bernie Siegel energizes listeners to live life with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate its ... Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center in ... the gold standard for high-definition, in-ear earphones. This classic earphone has been updated ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... online continuing education for EMS and firefighting professionals, has released four new continuing ... These new courses are taught live in an online classroom and meet the ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... partnership with Sigfox in the U.S.A. to offer Internet of Things ... new offerings on large-scale environmental sensor deployments such as monitoring solutions used to ...
(Date:1/17/2017)... ... 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company focused on ... for its dental gel that shows significant reduction in plaque levels and gum inflammation ... study was conducted at the Beckman Laser Institute at UC Irvine and has been ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research and Markets has announced the addition of the ... their offering. ... This new report revisits the market potential for self-healing materials from ... 2015. Self-healing is an area of smart coatings and materials with ... potential of $2.7 billion ($US) by 2020. However, in any market ...
(Date:1/17/2017)... TEL AVIV, Israel , January 17, 2017 ... , TyrNovo, Ltd.   KIT-302 Development On ... the FDA in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: ... a business update call on Monday, January 23 rd at 8:30am Eastern ...
(Date:1/17/2017)... 2017  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, plans to announce ... 2016 after the market closes on Wednesday, February 1, ... p.m. ET that day to discuss those results. ... 407-8037 or (201) 689-8037.  For 72 hours following the ...
Breaking Medicine Technology: